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Abstract
Introduction
Antiretroviral therapy (ART) has been successfully introduced in low-middle income coun-
tries. However an increasing rate of ART failure with resistant virus is reported. We therefore
described the pattern of drug resistance mutations at antiretroviral treatment (ART) failure in
a real-life Tanzanian setting using the remote genotyping procedure and thereafter pre-
dicted future treatment options using rule-based algorithm and the EuResist bioinformatics
predictive engine. According to national guidelines, the default first-line regimen is tenofovir
+ lamivudine + efavirenz, but variations including nevirapine, stavudine or emtricitabine can
be considered. If failure on first-line ART occurs, a combination of two nucleoside reverse
transcriptase inhibitors (NRTIs) and boosted lopinavir or atazanavir is recommended.
Materials and methods
Plasma was obtained from subjects with first (n = 174) or second-line (n = 99) treatment fail-
ure, as defined by clinical or immunological criteria, as well as from a control group of ART
naïve subjects (n = 17) in Dar es Salaam, Tanzania. Amplification of the pol region was per-
formed locally and the amplified DNA fragment was sent to Sweden for sequencing (split
genotyping procedure). The therapeutic options after failure were assessed by the geno-
typic sensitivity score and the EuResist predictive engine. Viral load was quantified in a sub-
set of subjects with second-line failure (n = 52).
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Results
The HIV-1 pol region was successfully amplified from 55/174 (32%) and 28/99 (28%) sub-
jects with first- or second-line failure, respectively, and 14/17 (82%) ART-naïve individuals.
HIV-1 pol sequence was obtained in 82 of these 97 cases (84.5%). Undetectable or very low
(<2.6 log10 copies/10−3 L) viral load explained 19 out of 25 (76%) amplification failures in
subjects at second-line ART failure. At first and second line failure, extensive accumulation
of NRTI (88% and 73%, respectively) and NNRTI (93% and 73%, respectively) DRMs but a
limited number of PI DRMs (11% at second line failure) was observed. First line failure sub-
jects displayed a high degree of cross-resistance to second-generation NNRTIs etravirine
(ETR; 51% intermediate and 9% resistant) and rilpivirine (RPV; 12% intermediate and 58%
resistant), and to abacavir (ABC; 49% resistant) which is reserved for second line therapy in
Tanzania. The predicted probability of success with the best salvage regimen at second-line
failure decreased from 93.9% to 78.7% when restricting access to the NRTIs, NNRTIs and
PIs currently available in Tanzania compared to when including all approved drugs.
Discussion
The split genotyping procedure is potential tool to analyse drug resistance in Tanzania but
the sensitivity should be evaluated further. The lack of viral load monitoring likely results in a
high false positive rate of treatment failures, unnecessary therapy switches and massive
accumulation of NRTI and NNRTI mutations. The introduction of regular virological monitor-
ing should be prioritized and integrated with drug resistance studies in resource limited
settings.
Introduction
In 2015, more than 500 000 human immunodeficiency virus (HIV) infected subjects in low-
middle income countries received second-line antiretroviral therapy (ART). A recent model-
ling study estimated that the number of subjects on second-line ART will increase substan-
tially, and by 2020 between 0.5 million and 3 million people in sub-Saharan Africa (SSA) will
need second line therapy [1]. The World Health Organization (WHO) recommends a regimen
of a ritonavir-boosted protease inhibitor (PI/r) plus two nucleoside or nucleotide reverse
transcriptase inhibitors (NRTI) for second-line ART in SSA and this approach is becoming
increasingly common [2, 3]. Studies so far have demonstrated sustained viral suppression for
up to two years among the majority of adult [2, 3] and paediatric [4] subjects undergoing sec-
ond-line treatment following first-line failure in SSA. However, ART failure and the presence
of major PI mutations have been reported in a minority of South Africans given PI/r contain-
ing second-line ART [5].
In Tanzania, ART has been freely available since 2004. In 2015, the prevalence of HIV-1
infection was 4.7% among adults and the ART coverage was estimated to be 53% [6]. Accord-
ing to national guidelines [7], the default first-line regimen (given to HIV-1-infected subjects
at WHO stage 3 and 4 or with CD4 < 500 cells/10−6 L) is tenofovir (TDF) + lamivudine (3TC)
+ efavirenz (EFV) although the NRTIs may be changed to other available options such as zido-
vudine (AZT) or emtricitabine (FTC) and EFV may be replaced by nevirapine (NVP) under
certain conditions. Treatment failure is identified using clinical and immunological parame-
ters while virological monitoring, although recommended, is not part of routine clinical
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practice. If failure on first-line ART occurs, a combination of two NRTIs (including TDF, AZT
or abacavir [ABC] depending on first line regimen) and boosted lopinavir (LPV/r) or atazana-
vir (ATV/r) is recommended. However, in case of second-line ART failure no third-line regi-
men is described in the national guidelines [7] and few drug options remain—no PIs other
than lopinavir and atazanavir, or drugs of newer classes such as entry inhibitors or integrase
inhibitors, are currently available in Tanzania.
This cross-sectional study aimed to describe the viral genotypic pattern at treatment failure
of first-line ART as well as second-line PI/r-based ART in a real-life Tanzanian setting using
the established clinical and immunological failure (CIF) criteria. Since drug genotypic resis-
tance testing (GRT) is not readily available in SSA, we used the “split genotyping procedure”
[8], where PCR amplification is performed locally while sequencing is carried out at a remote
reference laboratory. Drug susceptibility was inferred by rule-based genotypic sensitivity score
(GSS) algorithm and the EuResist bioinformatics predictive engine was used to predict the
probability of success of future treatment options [9].
Materials and methods
Ethical approval
Ethical approval for carrying out the study was obtained from the Senate Research and Publi-
cations Committee at the Muhimbili University of Health and Allied Sciences (Ref. No. MU/
01/1022/0122/10). Written informed consent was obtained from the subjects included in the
study. All participants were given a copy of the signed consent form, which contained infor-
mation about the study and contact details of the principal investigator and the ethics review
board, both in English and Kiswahili.
Subjects
Subjects with suspected first or second line treatment failure were approached consecutively at
two clinics; Muhimbili National Hospital and Amtulabhai Karimjee Treatment failure Clinic
in Dar es Salaam, Tanzania, between June 2009 and September 2014. As viral load testing is
not part of clinical practice in Tanzania, identification of subjects with ART failure was based
on CIF only [10]. WHO guidelines for a public health approach to ART define immunological
failures as: a CD4 count decrease to below baseline in the absence of concurrent infections, a
decrease of more than 50% from the peak value, or persistent CD4 below 100 cells/mm3 while
on treatment [10]. One-hundred-seventy-four consenting subjects with first-line ART failure
and 99 consenting subjects with second-line ART failure were recruited. The sample size was
obtained based on what was possible to access considering time and resources available. In
addition, 17 treatment naïve HIV-1 infected subjects from the Amtulabhai Karimjee Treat-
ment failure Clinic who consented were included in the study as a control group (to test the
split genotyping procedure using patient samples likely to have high viral loads and also to
compare drug resistance mutation [DRM] profiles). Demographical and clinical information,
ART exposure (dates and drug combinations), WHO stage and CD4 counts were extracted
from patient charts.
CD4 cells were determined by routine flow cytometry at the Muhimbili National Hospital.
Plasma from a subgroup of 52 subjects with CIF on second line PI/r-based therapy, of which
27 were PCR positive and 25 were PCR negative, were tested for HIV-RNA using COBAS
AmpliPrep/Cobas TaqMan HIV-1 test v 2.0 (CAP/CTM 48) (Roche Diagnostics, Basel, Swit-
zerland) at the National Health Laboratory Quality and Training Centre, Dar es Salaam.
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Genotypic resistance testing (GRT)
GRT was achieved using the previously described split genotyping procedure [8] in which the
first steps of GRT is performed at a local laboratory and the second steps at a centralized labo-
ratory. RNA was thus extracted from plasma locally at Muhimbili University of Health and
Allied Sciences (MUHAS) by the QIAamp Viral RNA Mini Kit (Qiagen, Sollentuna, Sweden),
followed by reverse-transcription PCR (RT-PCR) to generate cDNA using ImProm-II Reverse
Transcription System (Promega Biotech, Nacka, Sweden), according to the manufacturer’s
instructions. Nested pol gene amplification was carried out according to EuResist guidelines,
as described elsewhere [11] and visualized by gel electrophoresis. The PCR products were puri-
fied using QIAquick PCR Purification Kit (Qiagen). Thereafter, the purified PCR products
were sent to the Division of Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden,
and subjected to bi-directional population sequencing.
Sequences were manually scrutinized and edited using Geneious R6.1.6 (Biomatters,
Auckland, New Zealand). Sequences with full length protease gene (PR; 1–99 aa) and
partial reverse transcriptase gene (RT; 1–230) were used for further analysis. For positions
where a second peak was observed with peak height50% of the main peak, a wobble nucle-
otide was assigned. The sequences were deposited to GenBank with accession numbers
KX775225-KX775306.
HIV-1 subtyping was performed with REGA version 3.02 [12] followed by phylogenetic
tree analysis with reference sequences in PhyML [13]. The reference sequences were down-
loaded from Los Alamos database (www.hiv.lanl.gov). Multiple sequence analysis was per-
formed in ClustalW algorithm incorporated in Geneious R6.1.6. The alignment file was used
for phylogenetic analysis by maximum likelihood method in PhyML with the general time
reversible plus gamma substitution model (GTR+G) as best fitted model identified by the
FindModel tool (http://www.hiv.lanl.gov/content/sequence/findmodel/findmodel.html). The
approximate Likelihood Ratio Test (aLRT) was applied for branch support and the tree con-
sisting of only Tanzanian sequences was visualized using FigTree (http://tree.bio.ed.ac.uk/
software/figtree/). For clustering analysis, 5–7 sequences per cluster plus 3 outliers were sub-
mitted to the HIV-1 BLAST tool. The top three hits per sequence were downloaded and
aligned to generate a new phylogenetic tree as described above. The presence of drug resistance
mutations was assessed by using the Stanford HIVdB online tool [14].
Genotypic sensitivity scores (GSS) and prediction of optimal future
therapy
For assessment of GSS for current and future drug options, Rega version 9.1.0 [15] was
employed. Also, the EuResist Prediction Engine (http://engine.euresist.org/) was used for pre-
diction of the optimal salvage treatment regimen, based on the genotype at failure.
Statistics
Data were analysed using SPSS Statistics 22 (IBM Corporation, Armonk NY, USA) and graphs
were generated with the aid of GraphPad Prism 5 (GraphPad Software, La Jolla CA, USA).
Descriptive analysis was performed: mean or median and interquartile range (IQR) was used
for summarising continuous variables, and frequencies and percentages for categorical vari-
ables. A p-value< 0.05 was considered significant. For analyses examining the correlation
between viral load and CD4, and between viral load and treatment duration, nonparametric
correlation analysis (Spearman’s rho, two-tailed) was used in SPSS.
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Results
PCR amplification outcome, sample population and viral load test results
Using the split genotyping procedure, 14 of 17 (82%) samples from ART-naïve individuals
were successfully amplified, of which 13 yielded pol gene sequences suitable for further analy-
sis. For first-line and second-line failures respectively, as defined by CIF criteria, only 55 of 174
(32%) and 28 of 99 (28%) samples were successfully amplified, with corresponding 43 and 26
sequences generated. Clinical information about the subjects for whom sequencing succeeded
is given in Table 1 (see also S1 File). All subjects were above 18 years old except for five first
line failure subjects (aged 5, 7, 14, 16 and 17 respectively) and one second line failure patient
(aged 15).
To determine whether the low rate of amplification success was due to failure of the meth-
odology or due to misclassification of treatment failure by the CIF criteria, viral load testing
was performed in 52 subjects having second-line CIF for whom residual plasma was available,
of which 27 had successfully amplified HIV-1 pol region while for the remaining 25 PCR
amplification had been unsuccessful despite decreasing CD4 counts indicating treatment fail-
ure. The results revealed that for the majority of second-line samples for which PCR amplifica-
tion was unsuccessful (n = 25), HIV-RNA levels were below the limit of quantification (target
not detected; n = 2 or<1.3 log10 copies/10
−3 L; n = 4) or very low (1.3–2.6 log10 copies/10
−3 L;
n = 13) or low (2.6–3 log10 copies/10
−3 L; n = 3). Only three samples (12%) were> 3 log10 cop-
ies/10−3 L (3.27 log10 copies/10
−3 L; 4.74 log10 copies/10
−3 L and 5.54 log10 copies/10
−3 L). Con-
sequently, among the samples tested for viral load, PCR amplification was successful in 27/30
(90%) of the samples with a viral load of>3 log10 copies/10
−3 L. Among the PCR-positive sec-
ond-line failure samples (n = 27), the viral load ranged between 3.06 and 5.74 log10 copies/10
−3
L. For the 26 samples which generated usable sequences and were included in the genotypic
analysis, the median viral load was 4.8 log10 copies/10
−3 L (IQR 4.0, 5.4). There was no signifi-
cant correlation between viral load and CD4 at time of failure. Neither was there a correlation
between viral load and treatment duration (Spearman’s rho, two-tailed).
Drug resistance mutations at first- and second-line failures
Among 43 first-line failing subjects from whom a pol sequence was obtained, almost all (37/43;
86%) had1 NNRTI mutation as well as1 NRTI mutation. The proportion of subjects with
NRTI and NNRTI mutations increased with the duration of ART. For those treated <36
months (n = 9 out of 38 subjects with data on ART duration), six subjects (67%) had NRTI
mutations and seven subjects (78%) had NNRTI mutations (one patient had NNRTI muta-
tions only and six had both NRTI and NNRTI mutations). For those treated 36–60 months
(n = 24), 23 of 24 subjects (96%) had NRTI mutations and similarly 23 of 24 subjects (96%)
had NNRTI mutations (100% had either NRTI and/or NNRTI mutations: NRTI only: 1 (4%);
NNRTI only: 1 (4%); both NRTI and NNRTI: 22 (95%)). For the five subjects treated >60
months, all subjects had both NRTI and NNRTI mutations (Fig 1). For comparison, out of the
13 treatment naïve subjects, one displayed the K103N mutation and one the E138A mutation.
Only three out of 26 (11.5%) subjects failing PI/r-based second-line ART with detectable
viral load and a readable sequence had major PI mutations (V82A; V32I + I47A; M46I + I54V
+ V82A). From a public health point of view in a setting without access to viral load testing,
the rate of major PI mutation was only 3% of the 99 subjects considered to have second-line
ART failure, according to CIF criteria. Among the 26 subjects failing second-line therapy,
17 (65%) had both NRTI and NNRTI mutations and 4 (15%) had either NRTI or NNRTI
mutations.
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Assessment of future options after therapy failure
Among first-line ART failures, there was a widespread resistance to the first generation
NNRTI, efavirenz and nevirapine (93% resistant for both drugs), and a high degree of cross-
resistance to second-generation NNRTIs etravirine (ETR; 51% intermediate and 9% resistant)
and rilpivirine (RPV; 12% intermediate and 58% resistant). Forty-nine percent (49%) of first-
Table 1. Demographics of subjects with successfully obtained HIV-1 pol sequences.
Characteristic ART-naïve (n = 13) 1st line failure (n = 43) 2nd line failure (n = 26)
Age median years (IQR) 33 (28, 36) 38 (33, 48) 39 (31, 46)
Range 25–59 5–63 15–78
missing, n (%) 0 (0.0%) 1 (2.3%) 0 (0.0%)
Gender % Female 100% 60.5% 73.1%
missing, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Time since diagnosis median years (IQR) 3.5 (0.03, 5.6) 4.7 (3.4, 6.3) 6.7 (4.9, 7.2)
missing, n (%) 0 (0.0%) 6 (13.0%) 6 (23.1%)
CD4 at start of ART median cells/μl (IQR) N.A. 50 (11, 175) 109 (28, 180)
missing, n (%) 6 (13.0%) 2 (7.7%)
CD4 at sampling median cells/μl (IQR) 445 (147, 579) 24 (7, 57) 93 (32, 141)
missing, n (%) 7 (16.3%) 2 (7.7%)
Viral load log10 copies/mL median (IQR) N.A. N.A. 4.6 (4.0, 5.2)
missing, n (%) 1 (3.8%)
WHO stage at sampling n (%)
I 7 (53.8%) 0 (-) 1 (3.8%)
II 4 (30.8%) 9 (20.9%) 8 (30.8%)
III 1 (7.7%) 14 (32.6%) 11 (42.3%)
IV 1 (7.7%) 17 (39.5%) 4 (15.0%)
Missing 0 (-) 3 (7.0%) 2 (7.7%)
ART duration months mean (IQR)
1st line therapy N.A. 49.1 (37.1, 56.7) 63.4 (40.7, 74.5)
missing, n (%) 5 (11.6%) 3 (11.5%)
2nd line therapy N.A. N.A. 17.7 (2.9, 31.4)
missing, n (%) 3 (11.5%)
ART initiated n (%) N.A.
1st line regimen
d4T + 3TC + NVP 19 (44.2%) 11 (42.3%)
AZT + 3TC + NVP 11 (25.6%) 7 (26.9%)
AZT + 3TC + EFV 8 (18.6%) 4 (15.4%)
TDF + FTC/3TC + EFV 3 (7.0%) 0 (-)
d4T + 3TC + EFV 0 (-) 3 (15.4%)
Missing 2 (4.7%) 1 (3.8%)
2nd line regimen
TDF + FTC + LPV/r 19 (73.1%)
ABC + ddI + LPV/r 3 (11.5%)
ABC + 3TC +LPV/r 1 (3.8%)
TDF + FTC +ATV/r 1 (3.8%)
Missing 2 (7.7%)
ART = antiretroviral therapy, d4T = stavudine, 3TC = lamivudine, NVP = nevirapine, AZT = zidovudine, EFV = efavirenz, TDF = tenofovir disoproxil
fumarate, FTC = emtricitabine, LPV/r = ritonavir-boosted lopinavir, ABC = abacavir, ddI = didanosine, ATV/r = ritonavir-boosted atazanavir.
https://doi.org/10.1371/journal.pone.0178942.t001
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Fig 1. Antiretroviral drug resistance mutations in Tanzanian subjects at first line clinico-immunological ART failure. A)
stratified by treatment duration (n = 38); B) stratified by CD4 cells at failure (n = 36).
https://doi.org/10.1371/journal.pone.0178942.g001
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line failures also displayed cross-resistance to ABC, which in general is reserved for second
line therapy in Tanzania. Second line failure subjects displayed somewhat lower resistance to
EFV and NVP (69% resistance for both drugs) and lower cross-resistance to ETR (15% inter-
mediate and 0% resistant) and RPV (8% intermediate and 31% resistant), while resistance to
FTC and 3TC was high (58% resistant for both drugs). (Fig 2).
Future therapy options were assessed by the GSS approach (Fig 2) and by the EuResist pre-
diction engine (Fig 3). For the currently most common second-line regimen in Tanzania
(TDF + FTC + LPV/r), the combined median GSS was 2.0 (IQR 2.0, 2.5) for all first-line failure
subjects, corresponding to two active drugs, which is the minimum target GSS for treatment-
experienced subjects with limited treatment options (https://rega.kuleuven.be/cev/avd/files/
software/rega_algorithm/Rega_HIV1_Rules_v9.1.0.pdf).
The success probability of the predicted optimal therapy was also investigated using the
EuResist prediction engine for all first-line and second-line failure subjects, given their indi-
vidual DRM profile. Firstly, when considering the TDF + FTC + LPV/r combination (the most
widely used second line antiretroviral regimen in Tanzania), the median success probability
was 87.7% (range 64.2–94.2%) for 39 out of the 43 first-line failure subjects. For the remaining
four subjects, this combination was not among the top ten recommended ART regimens (and
hence no estimated success probability was given). Two of these subjects had DRM patterns
which confer resistance to FTC according to the REGA criteria, and one of them additionally
displayed intermediate resistance to TDF [15]. Secondly, two hypothetical scenarios were com-
pared: 1) all approved NRTIs, NNRTIs and PIs were available for building the treatment regi-
men, and 2) only currently available antiretrovirals in Tanzania were included in the optimal
future regimen (ABC, FTC, didanosine (ddI), 3TC, d4T, TDF, AZT, EFV, NVP, ATV/r, LPV/
r). Among the first line failure cases, the mean success probability was reduced from 94.9% to
85.0% (reduction range 0.2–31.3%) when restricting antiretroviral access to the current situa-
tion in Tanzania (Fig 3A). For the second-line failure subjects, the corresponding mean reduc-
tion was from 93.9% to 78.7% (reduction range 1.7–41.2%) (Fig 3B).
Molecular epidemiology of HIV-1 subtypes
The subtype analysis identified 41% subtype A1, 27% subtype C, 9% subtype D, 5%
CRF10_CD, 17% recombinant (A1C, A1D or other D recombinants), and 1% unclassified.
Subtype A1 pol sequences primarily clustered with other sequences from Tanzania, Kenya and
Fig 2. Genotypic sensitivity scores for all reverse transcriptase and protease inhibitors. Percentage (%) of patient strains classified as
susceptible, intermediate or resistant as per the Rega V.9.1.0 algorithm; first line failure (n = 43) and second line virological failure cases (n = 26)
presented with separate paired bars (first line left bar, second line right bar).
https://doi.org/10.1371/journal.pone.0178942.g002
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Uganda (data not shown). Subtype D pol sequences clustered with other sequences from Tan-
zania and Uganda. Subtype C pol sequences clustered together with pol sequences from Tanza-
nia, South Africa, Zambia and Botswana (9 sequences) or with pol sequences from Ethiopia (7
sequences).
Discussion
Despite the increasing use of PI-based second-line ART in SSA, little is known about the real-
life treatment outcomes, DRM patterns at therapy failure, and further treatment options there-
after. As viral load monitoring is not yet part of routine clinical practice in Tanzania, treatment
failure is defined by clinico-immunological criteria. The study therefore evaluated the conse-
quences of using these criteria for the definition of ART failure and the assessment of drug
resistance. Also, since access to point of care (POC) diagnostics is lacking also for GRT all over
the world [16], the split genotyping procedure for assessment of DRM was evaluated.
In pilot evaluations, the “split genotyping procedure” has shown that laboratory technicians
without or with limited background in molecular diagnostics can be successfully trained to
generate HIV DNA fragments to be shipped and sequenced remotely with satisfactory results
[8], although this needs further validation including viral load verification given the high PCR
failure rates. In the present study, the first part of the split GRT design was run at MUHAS
(Dar es Salaam, Tanzania) and the second part at Karolinska Institutet (Stockholm, Sweden).
Fig 3. Success probability of future regimen by the EuResist prediction engine. Prediction is based on drug resistance mutation profile and
data on previous drug exposure, age, gender and CD4 at failure. Results are presented in ordered of increasing difference between a scenario
where all approved NRTIs, NNRTIs and PIs are available versus currently available drugs in Tanzania. A) subjects failing first line therapy; B)
subjects failing second line therapy (viral load included in prediction model).
https://doi.org/10.1371/journal.pone.0178942.g003
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The sequencing at Karolinska Institutet was successful in a large number of samples (82/97;
84.5%) for which a HIV DNA fragment was obtained at MUHAS, despite that a high degree of
viral heterogeneity at the subtype level was found (subtypes A1, C, D, CRF10_CD, CRF A1C,
A1D, other D recombinants and unclassified). Viral heterogeneity and spurious PCR products
generating overlapping sequences could be explanatory factors behind sequencing failure
despite successful PCR amplification (n = 15).
Although we did not perform any formal analysis of the sensitivity of the approach, the split
design is likely to be a valid alternative to e.g. GRT on dried blood spots or other approaches of
POC diagnostics for GRT [16]. We recognize that there might also be some additional issues
related to sending amplified non-infectious proviral DNA through air-flights but according to
our experience at the present global situation, the costs is low and the material is not consid-
ered to be a biohazard. Also, we showed that it can be used to describe the subtype distribution
in a region, at least when a fragment of sufficient length is used.
The HIV-1 pol gene amplification success rate at MUHAS was however very low when we
tested a large number of plasma samples from subjects who had been defined as first-line ART
failures (success rate 38%) or second-line PI/r-based ART failures (success rate 28%) by clin-
ico-immunological assessment in real-life settings by Tanzanian physicians. When we deter-
mined the viral load in a subset of the second-line failures (around half of which had successful
HIV-1 pol amplification and around half of which had unsuccessful HIV-1 pol amplification)
by quantitative PCR it was found that almost all subjects for whom the HIV-1 pol amplification
had failed, had undetectable or very low viral load. In contrast, most (27/30; 90%) of the sub-
jects with a viral load>3 log10 copies/10
−3 L had amplification success. It can be argued that
the local PCR failed in three subjects with a viral load of 2.6–3 log10 copies/10
−3 L, which in a
high-income country would be a potential problem. However, it is important to emphasize
that WHO recommends switch to a new regimen when the viral load is > 1000 copies/ml (3
log10 copies/10
−3 L) since the risk of HIV transmission is very low below this threshold[10],
and that frequently a viral load between 2.6–3 log10 copies/10
−3 L can be handled through
increased adherence support[17], avoiding unnecessary switches in a situation with few thera-
peutic alternatives. Although we did not test the viral load in our first-line failures it seems
likely that a similar pattern was the major cause of the amplification failures. These subjects
may thus have been unnecessarily switched from an efficient ART regimen. Other recent stud-
ies from Tanzania [18, 19], Kenya [20] as well as a multi-center study across six SSA countries
[21] demonstrated poor correlation between immunological and virological failure. For exam-
ple, Sigaloff et al. showed that 46.9% of subjects who were defined as treatment failures based
on the clinico-immunological criteria were found to have an HIV RNA level<1000 copies/
10−3 L (<3 log10 copies/10
−3 L) [21]. In our study the proportion was similar; 42%.
Furthermore, the subjects with the longest duration on a failing first line regimen in our
study had accumulated the highest number of DRMs. Other studies have demonstrated that
absence of virological monitoring and a delayed switch of therapy lead to a high degree of
accumulation of DRMs [22] and an increased mortality [23]. Since 2013, WHO have included
virological testing as the preferred monitoring strategy [10], which may eventually enable
affordable viral load testing in resource-limited settings and shift the cost/benefit balance in
favour of implementing virological monitoring on a broader scale. In addition, improved
access to GRT, e.g. through the split genotyping procedure or other POC tests could inform
on the best future regimens once treatment failure has been confirmed by viral load testing.
In our cohort of 26 HIV-1 infected subjects with virologically confirmed failure on second-
line therapy, we detected major PI mutations in 11.5% (three individuals), which is the first
report on emergence of major PI mutations in Tanzania. This data mirrors a larger study
including 490 subjects receiving LPV/r in South Africa where the prevalence was 11% [5].
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However it must be noted that the South African study included 44% of children (<15 years of
age) and this may have contributed to the prevalence described.
In order to evaluate the remaining treatment possibilities for the failing subjects, we ana-
lysed the GSS as well as predicted the remaining options by the EuResist predictive engine [9].
Notably using GSS, 49% of first-line failure cases displayed resistance to ABC and 21% to TDF,
which are used together with LPV/r as the standard second-line regimen in Tanzania. Addi-
tionally, more than half of first-line failure subjects and 15% of second-line failure subjects car-
ried virus classified as intermediate resistant or resistant to ETR, while the level of resistance to
RPV was even higher. The results show thus the potential value of PI/r inhibitors in second-
and third-line ART in Tanzania as well as second-generation integrase inhibitors in the future.
The probability of success based on a predicted optimal therapy was also investigated using the
EuResist prediction engine. Despite the high burden of NRTI mutations, when considering the
TDF + FTC + LPV/r regimen the median success probability was as high as 87.7% (range 64.2–
94.2%) for 39 of the 43 first-line failure subjects. These results are in line with the finding of the
EARNEST trial, in which NRTIs retained substantial virological activity when given with a PI in
second-line therapy [2]. It must be noted however that predictions of optimal future regimen
demonstrated a mean reduction of success probability among second-line failure subjects from
93.9% to 78.7% when the choices were restricted to the NRTIs, NNRTIs and PIs currently avail-
able in Tanzania compared to when including all approved drugs of these categories. A limitation
of this analysis was allowing 3-class regimens, which are uncommonly used in the clinical setting.
In summary, our study underscores the importance of using viral load for monitoring ART
in resource-limited settings since the clinico-immunological monitoring in our study resulted
in a very high frequency of unnecessary ART switches but also to an accumulation of extensive
NRTI and NNRTI resistance in subjects failing with undetected viremia. When viral load is
introduced for monitoring ART in these settings, our split genotyping procedure could be a
valid and simple method for monitoring drug resistance to present and future antiretroviral
agents although further validation is required to address potential PCR amplification issues. If
a viral sequence can be obtained, bioinformatics methods can help the physicians to optimize
the ARV regimens, especially for third-line ART in settings with limited therapeutic options.
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